About: Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light
Creator	Bowen, Richard Ragan, Izabela Goodrichid, Raymond Hartson, Lindsay
Source	Medline; PMC
abstract	BACKGROUND: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has recently been identified as the causative agent for Coronavirus Disease 2019 (COVID-19). The ability of this agent to be transmitted by blood transfusion has not been documented, although viral RNA has been detected in serum. Exposure to treatment with riboflavin and ultraviolet light (R + UV) reduces blood-borne pathogens while maintaining blood product quality. Here, we report on the efficacy of R + UV in reducing SARS-CoV-2 infectivity when tested in human plasma and whole blood products. STUDY DESIGN AND METHODS: SARS-CoV-2 (isolate USA-WA1/2020) was used to inoculate plasma and whole blood units that then underwent treatment with riboflavin and UV light (Mirasol Pathogen Reduction Technology System, Terumo BCT, Lakewood, CO). The infectious titers of SARS-CoV-2 in the samples before and after R + UV treatment were determined by plaque assay on Vero E6 cells. Each plasma pool (n = 9) underwent R + UV treatment performed in triplicate using individual units of plasma and then repeated using individual whole blood donations (n = 3). RESULTS: Riboflavin and UV light reduced the infectious titer of SARS-CoV-2 below the limit of detection for plasma products at 60–100% of the recommended energy dose. At the UV light dose recommended by the manufacturer, the mean log reductions in the viral titers were ≥ 4.79 ± 0.15 Logs in plasma and 3.30 ± 0.26 in whole blood units. CONCLUSION: Riboflavin and UV light effectively reduced the titer of SARS-CoV-2 to the limit of detection in human plasma and by 3.30 ± 0.26 on average in whole blood. Two clades of SARS-CoV-2 have been described and questions remain about whether exposure to one strain confers strong immunity to the other. Pathogen-reduced blood products may be a safer option for critically ill patients with COVID-19, particularly those in high-risk categories.
has issue date	2020-05-29(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0233947
bibo:pmid	32470046
has license	cc-by
sha1sum (hex)	358ca78a359887f588c06e229532d41e1d4040d7
schema:url	https://doi.org/10.1371/journal.pone.0233947
resource representing a document's title	Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light
has PubMed Central identifier	PMC7259667
has PubMed identifier	32470046
schema:publication	PLoS One
resource representing a document's body	covid:358ca78a359887f588c06e229532d41e1d4040d7#body_text
is schema:about of	named entity 'Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)' named entity 'infectivity' named entity 'viral' named entity 'plasma' named entity 'reduction' named entity 'plasma' named entity 'SARS-CoV-2' named entity 'blood products' named entity 'riboflavin' named entity 'SARS-CoV-2' named entity 'Severe Acute Respiratory Syndrome Coronavirus 2' named entity 'blood products' named entity 'blood-borne pathogens' named entity 'SARS-CoV-2' named entity 'Coronavirus Disease' named entity 'SARS-CoV-2 virus' named entity 'riboflavin and UV light' named entity 'infectivity' named entity 'BLOOD PRODUCTS' named entity 'causative agent' named entity 'blood product' named entity 'plasma' named entity 'viral RNA' named entity 'ultraviolet light' named entity 'blood transfusion' named entity 'ABILITY' named entity 'TREATMENT' named entity 'BLOOD-BORNE PATHOGENS' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2' named entity 'EFFICACY' named entity 'BLOOD PRODUCT' named entity 'SARS-COV-2 INFECTIVITY' named entity 'HUMAN PLASMA' covid:arg/358ca78a359887f588c06e229532d41e1d4040d7 named entity 'human plasma' named entity 'WHOLE BLOOD' named entity 'DETECTED' named entity 'serum' named entity 'Pathogen' named entity 'Disease' named entity 'tested' named entity 'ability' named entity 'transmitted' named entity 'reduces' named entity 'reducing' named entity 'blood product' named entity 'efficacy' named entity 'identified' named entity 'maintaining' named entity 'SERUM' named entity 'REPORT' named entity 'Here' named entity 'RNA' named entity 'Pathogen' named entity 'UV light' named entity '2019' named entity 'riboflavin' named entity 'blood transfusion' named entity 'serum' named entity 'blood-borne pathogens' named entity 'causative' named entity 'riboflavin' named entity 'blood' named entity 'ultraviolet light' named entity 'PLASMA' named entity 'Coronavirus' named entity 'virus' named entity 'REDUCING' named entity 'VIRAL RNA' named entity 'SARS-CoV-2' named entity 'MAINTAINING' named entity 'RECENTLY' named entity 'BLOOD TRANSFUSION' named entity 'IDENTIFIED' named entity 'TRANSMITTED BY' named entity 'HERE' named entity 'DOCUMENTED' named entity 'AGENT'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software